Clinical Data Updates on Adjuvant Pertuzumab/Trastuzumab for HER2+ Early Breast Cancer


A review of recently reported data on the use of adjuvant pertuzumab/trastuzumab for the treatment of HER2+ early breast cancer, including data from the APHINITY and PHranceSCa trials.

Related Videos
Video 4 - "EMERALD-1 Study: Significance as Presented at ASCO GI 2024"
Video 3 - "Determining Transarterial Chemoembolization (TACE) Candidacy for Patients with HCC"
Reshma Jagsi, MD, DPhil, Emory University
Martin H. Voss, MD, an expert on renal cell carcinoma
Laurence Albigès, MD, PhD, an expert on renal cell carcinoma
A panel of 4 experts on hematologic malignancies
Jane L. Meisel, MD
Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center